BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.

Financial Report
Opdivo sales have declined, but are expected to rise in 2021

Bristol-Myers Squibb Co. reported its third consecutive quarter of declining Opdivo (nivolumab) sales in the US, and second consecutive quarterly sales decline globally, on 6 February. As a result, executives spent most of the company’s earnings call explaining that Bristol-Myers expects its PD-1 inhibitor to return to growth through new indications before Revlimid (lenalidomide) – acquired in the recently closed $76bn acquisition of Celgene Corp. – begins to face generics in 2022.

Opdivo continues to be overshadowed by Merck & Co. Inc.’s competing PD-1 inhibitor Keytruda (pembrolizumab), which dominates the first-line...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.